Atlas Trials

A Study to Evaluate the Safety and Immunogenicity of Omicron COVID-19 Vaccine (Vero Cell), Inactivated in Population 18 Years Old of Age and Above

Clinical trial NCT05365724 · UNKNOWN

Trial details

NCT number
NCT05365724
Sponsor
China National Biotec Group Company Limited
Status
UNKNOWN
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
COVID-19
Start date
2022-05-01
Primary completion
2023-10-01
Enrollment
280

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.